Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
1. 2763602-16-8
2. Icotrokinra [inn]
3. Muw8fp7hnz
4. Schembl23656544
5. Ex-a9714
6. Hy-p10587
7. Glycinamide, N-acetyl-3-mercapto-l-valyl-l-asparaginyl-l-threonyl-7-methyl-l-tryptophyl-n6-acetyl-l-lysyl-3-mercapto-l-valyl-o-(2-aminoethyl)-l-tyrosyl-3-(2-naphthalenyl)-l-alanyl-4-aminotetrahydro-2h-pyran-4-carbonyl-l-alpha-glutamyl-l-asparaginyl-3-(3-pyridinyl)-l-alanyl-n2-methyl-, Cyclic (1-->6)-disulfide
Molecular Weight | 1898.2 g/mol |
---|---|
Molecular Formula | C90H120N20O22S2 |
XLogP3 | -3.4 |
Hydrogen Bond Donor Count | 20 |
Hydrogen Bond Acceptor Count | 26 |
Rotatable Bond Count | 40 |
Exact Mass | g/mol |
Monoisotopic Mass | g/mol |
Topological Polar Surface Area | 709 |
Heavy Atom Count | 134 |
Formal Charge | 0 |
Complexity | 4100 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 12 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Fujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.
Fujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.
About the Company : Fujian Genohope Biotech Ltd, established in 2019, specializes in high-potency polypeptide APIs and solutions, offering global API and preparation production services. Co-founded by...
Details:
JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied in adults & adolescents 12 years of age & older with moderate-to-severe plaque PsO.
Lead Product(s): Icotrokinra,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 09, 2025
Lead Product(s) : Icotrokinra,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Icotrokinra Clears Skin in Tough Scalp and Genital Psoriasis Patients
Details : JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied in adults & adolescents 12 years of age & older with moderate-to-severe plaque PsO.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 09, 2025
Details:
JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied in adults & adolescents 12 years of age & older with moderate-to-severe plaque PsO.
Lead Product(s): Icotrokinra,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 10, 2025
Lead Product(s) : Icotrokinra,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Icotrokinra Clears Plaque Psoriasis in 75% Of Teens in Daily Pill Trial
Details : JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied in adults & adolescents 12 years of age & older with moderate-to-severe plaque PsO.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 10, 2025
Details:
Undisclosed
Lead Product(s): Icotrokinra,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 17, 2025
Lead Product(s) : Icotrokinra,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Par...
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 17, 2025
Details:
JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied for the treatment of moderate-to-severe ulcerative colitis.
Lead Product(s): Icotrokinra,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 10, 2025
Lead Product(s) : Icotrokinra,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Icotrokinra Meets Primary Endpoint in Ulcerative Colitis Study
Details : JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied for the treatment of moderate-to-severe ulcerative colitis.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 10, 2025
Details:
JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied in adults & adolescents 12 years of age & older with moderate-to-severe plaque PsO.
Lead Product(s): Icotrokinra,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 08, 2025
Lead Product(s) : Icotrokinra,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Icotrokinra Study Results Suggest Potential to Redefine Treatment Standards in Psoriasis
Details : JNJ-2113 (icotrokinra) is a first-in-class oral peptide that selectively blocks IL-23 receptor. It is being studied in adults & adolescents 12 years of age & older with moderate-to-severe plaque PsO.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 08, 2025
Details:
Undisclosed
Lead Product(s): Icotrokinra,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 04, 2025
Lead Product(s) : Icotrokinra,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 04, 2025
Details:
JNJ-2113 (icotrokinra) is a first and only targeted oral peptide that is designed to selectively block the IL-23R. It is under clinical development for the treatment of moderate-to-severe psoriasis.
Lead Product(s): Icotrokinra,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Protein
Sponsor: Protagonist Therapeutics
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 18, 2024
Lead Product(s) : Icotrokinra,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Protagonist Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Protagonist Announces Positive Results for Icotrokinra in Phase 3 Plaque Psoriasis
Details : JNJ-2113 (icotrokinra) is a first and only targeted oral peptide that is designed to selectively block the IL-23R. It is under clinical development for the treatment of moderate-to-severe psoriasis.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
November 18, 2024
Details:
JNJ-2113 is a first and only targeted oral peptide that is designed to selectively block the IL-23 receptor. It is under clinical development for the treatment of moderate-to-severe psoriasis.
Lead Product(s): Icotrokinra,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Protein
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 03, 2024
Lead Product(s) : Icotrokinra,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Data Shows JNJ-2113 Maintained Skin Clearance in Moderate-To-Severe Psoriasis
Details : JNJ-2113 is a first and only targeted oral peptide that is designed to selectively block the IL-23 receptor. It is under clinical development for the treatment of moderate-to-severe psoriasis.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 03, 2024
Details:
Under the Agreement, Janssen is conducting Phase 2b trial of JNJ-2113 (formerly known as PN-235), a first-in-class targeted oral peptide designed to selectively block the IL-23 receptor, in moderately to severely active ulcerative colitis.
Lead Product(s): Icotrokinra,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Protein
Sponsor: JANSSEN BIOTECH
Deal Size: $987.5 million Upfront Cash: $50.0 million
Deal Type: Licensing Agreement December 13, 2023
Lead Product(s) : Icotrokinra,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : JANSSEN BIOTECH
Deal Size : $987.5 million
Deal Type : Licensing Agreement
Details : Under the Agreement, Janssen is conducting Phase 2b trial of JNJ-2113 (formerly known as PN-235), a first-in-class targeted oral peptide designed to selectively block the IL-23 receptor, in moderately to severely active ulcerative colitis.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : $50.0 million
December 13, 2023
Details:
JNJ-2113 is a first and only targeted oral peptide that is designed to selectively block the IL-23 receptor. It is under clinical development for the treatment of moderate-to-severe psoriasis.
Lead Product(s): Icotrokinra,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Protein
Sponsor: Protagonist Therapeutics
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 27, 2023
Lead Product(s) : Icotrokinra,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Protagonist Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JNJ-2113 is a first and only targeted oral peptide that is designed to selectively block the IL-23 receptor. It is under clinical development for the treatment of moderate-to-severe psoriasis.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
November 27, 2023
ABOUT THIS PAGE
82
PharmaCompass offers a list of Icotrokinra API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Icotrokinra manufacturer or Icotrokinra supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Icotrokinra manufacturer or Icotrokinra supplier.
PharmaCompass also assists you with knowing the Icotrokinra API Price utilized in the formulation of products. Icotrokinra API Price is not always fixed or binding as the Icotrokinra Price is obtained through a variety of data sources. The Icotrokinra Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Icotrokinra manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Icotrokinra, including repackagers and relabelers. The FDA regulates Icotrokinra manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Icotrokinra API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Icotrokinra manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Icotrokinra supplier is an individual or a company that provides Icotrokinra active pharmaceutical ingredient (API) or Icotrokinra finished formulations upon request. The Icotrokinra suppliers may include Icotrokinra API manufacturers, exporters, distributors and traders.
click here to find a list of Icotrokinra suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Icotrokinra Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Icotrokinra GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Icotrokinra GMP manufacturer or Icotrokinra GMP API supplier for your needs.
A Icotrokinra CoA (Certificate of Analysis) is a formal document that attests to Icotrokinra's compliance with Icotrokinra specifications and serves as a tool for batch-level quality control.
Icotrokinra CoA mostly includes findings from lab analyses of a specific batch. For each Icotrokinra CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Icotrokinra may be tested according to a variety of international standards, such as European Pharmacopoeia (Icotrokinra EP), Icotrokinra JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Icotrokinra USP).